Literature DB >> 34358447

ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency.

Zhendong Cao1, Krista A Budinich1, Hua Huang2, Diqiu Ren1, Bin Lu3, Zhen Zhang2, Qingzhou Chen1, Yeqiao Zhou4, Yu-Han Huang3, Fatemeh Alikarami5, Molly C Kingsley5, Alexandra K Lenard5, Aoi Wakabayashi6, Eugene Khandros6, Will Bailis7, Jun Qi8, Martin P Carroll9, Gerd A Blobel6, Robert B Faryabi4, Kathrin M Bernt10, Shelley L Berger2, Junwei Shi11.   

Abstract

The transformed state in acute leukemia requires gene regulatory programs involving transcription factors and chromatin modulators. Here, we uncover an IRF8-MEF2D transcriptional circuit as an acute myeloid leukemia (AML)-biased dependency. We discover and characterize the mechanism by which the chromatin "reader" ZMYND8 directly activates IRF8 in parallel with the MYC proto-oncogene through their lineage-specific enhancers. ZMYND8 is essential for AML proliferation in vitro and in vivo and associates with MYC and IRF8 enhancer elements that we define in cell lines and in patient samples. ZMYND8 occupancy at IRF8 and MYC enhancers requires BRD4, a transcription coactivator also necessary for AML proliferation. We show that ZMYND8 binds to the ET domain of BRD4 via its chromatin reader cassette, which in turn is required for proper chromatin occupancy and maintenance of leukemic growth in vivo. Our results rationalize ZMYND8 as a potential therapeutic target for modulating essential transcriptional programs in AML.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IRF8; MEF2D; ZMYND8; acute myeloid leukemia; epigenetics; transcriptional addiction

Mesh:

Substances:

Year:  2021        PMID: 34358447      PMCID: PMC8932643          DOI: 10.1016/j.molcel.2021.07.018

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  109 in total

1.  Targeted in situ genome-wide profiling with high efficiency for low cell numbers.

Authors:  Peter J Skene; Jorja G Henikoff; Steven Henikoff
Journal:  Nat Protoc       Date:  2018-04-12       Impact factor: 13.491

2.  Somatic mutations precede acute myeloid leukemia years before diagnosis.

Authors:  Pinkal Desai; Nuria Mencia-Trinchant; Oleksandr Savenkov; Michael S Simon; Gloria Cheang; Sangmin Lee; Michael Samuel; Ellen K Ritchie; Monica L Guzman; Karla V Ballman; Gail J Roboz; Duane C Hassane
Journal:  Nat Med       Date:  2018-07-09       Impact factor: 53.440

3.  Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.

Authors:  T Holtschke; J Löhler; Y Kanno; T Fehr; N Giese; F Rosenbauer; J Lou; K P Knobeloch; L Gabriele; J F Waring; M F Bachmann; R M Zinkernagel; H C Morse; K Ozato; I Horak
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

4.  Mutant NPM1 Maintains the Leukemic State through HOX Expression.

Authors:  Lorenzo Brunetti; Michael C Gundry; Daniele Sorcini; Anna G Guzman; Yung-Hsin Huang; Raghav Ramabadran; Ilaria Gionfriddo; Federica Mezzasoma; Francesca Milano; Behnam Nabet; Dennis L Buckley; Steven M Kornblau; Charles Y Lin; Paolo Sportoletti; Maria Paola Martelli; Brunangelo Falini; Margaret A Goodell
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

5.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

6.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

7.  MELK is not necessary for the proliferation of basal-like breast cancer cells.

Authors:  Hai-Tsang Huang; Hyuk-Soo Seo; Tinghu Zhang; Yubao Wang; Baishan Jiang; Qing Li; Dennis L Buckley; Behnam Nabet; Justin M Roberts; Joshiawa Paulk; Shiva Dastjerdi; Georg E Winter; Hilary McLauchlan; Jennifer Moran; James E Bradner; Michael J Eck; Sirano Dhe-Paganon; Jean J Zhao; Nathanael S Gray
Journal:  Elife       Date:  2017-09-19       Impact factor: 8.140

8.  Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.

Authors:  Gerard L Brien; David Remillard; Junwei Shi; Matthew L Hemming; Jonathon Chabon; Kieran Wynne; Eugène T Dillon; Gerard Cagney; Guido Van Mierlo; Marijke P Baltissen; Michiel Vermeulen; Jun Qi; Stefan Fröhling; Nathanael S Gray; James E Bradner; Christopher R Vakoc; Scott A Armstrong
Journal:  Elife       Date:  2018-11-15       Impact factor: 8.713

9.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Authors:  Philipp Rathert; Mareike Roth; Tobias Neumann; Felix Muerdter; Jae-Seok Roe; Matthias Muhar; Sumit Deswal; Sabine Cerny-Reiterer; Barbara Peter; Julian Jude; Thomas Hoffmann; Łukasz M Boryń; Elin Axelsson; Norbert Schweifer; Ulrike Tontsch-Grunt; Lukas E Dow; Davide Gianni; Mark Pearson; Peter Valent; Alexander Stark; Norbert Kraut; Christopher R Vakoc; Johannes Zuber
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

10.  The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination.

Authors:  Verónica Delgado-Benito; Daniel B Rosen; Qiao Wang; Anna Gazumyan; Joy A Pai; Thiago Y Oliveira; Devakumar Sundaravinayagam; Wenzhu Zhang; Matteo Andreani; Lisa Keller; Kyong-Rim Kieffer-Kwon; Aleksandra Pękowska; Seolkyoung Jung; Madlen Driesner; Roman I Subbotin; Rafael Casellas; Brian T Chait; Michel C Nussenzweig; Michela Di Virgilio
Journal:  Mol Cell       Date:  2018-10-04       Impact factor: 17.970

View more
  5 in total

1.  A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify®.

Authors:  Lin Ming Lee; Eleni G Christodoulou; Pavithra Shyamsunder; Bei Jun Chen; Kian Leong Lee; Tsz Kan Fung; Chi Wai Eric So; Gee Chuan Wong; Enrico Petretto; Owen J L Rackham; S Tiong Ong
Journal:  Oncogene       Date:  2022-10-21       Impact factor: 8.756

2.  A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia.

Authors:  Taku Harada; Yaser Heshmati; Jérémie Kalfon; Monika W Perez; Juliana Xavier Ferrucio; Jazmin Ewers; Benjamin Hubbell Engler; Andrew Kossenkov; Jana M Ellegast; Joanna S Yi; Allyson Bowker; Qian Zhu; Kenneth Eagle; Tianxin Liu; Yan Kai; Joshua M Dempster; Guillaume Kugener; Jayamanna Wickramasinghe; Zachary T Herbert; Charles H Li; Jošt Vrabič Koren; David M Weinstock; Vikram R Paralkar; Behnam Nabet; Charles Y Lin; Neekesh V Dharia; Kimberly Stegmaier; Stuart H Orkin; Maxim Pimkin
Journal:  Genes Dev       Date:  2022-03-17       Impact factor: 12.890

3.  ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells.

Authors:  Maowu Luo; Lei Bao; Yan Chen; Yuanyuan Xue; Yong Wang; Bo Zhang; Chenliang Wang; Chase D Corley; Jeffrey G McDonald; Ashwani Kumar; Chao Xing; Yisheng Fang; Erik R Nelson; Jennifer E Wang; Yingfei Wang; Weibo Luo
Journal:  Sci Adv       Date:  2022-07-15       Impact factor: 14.957

4.  DSC2 Suppresses the Metastasis of Gastric Cancer through Inhibiting the BRD4/Snail Signaling Pathway and the Transcriptional Activity of β-Catenin.

Authors:  Chao Sun; Lei Wang; Dan-Dan Du; Jian-Bo Ji; Xiao-Xia Yang; Bing-Fang Yu; Peng-Fei Shang; Xiu-Li Guo
Journal:  Oxid Med Cell Longev       Date:  2022-09-06       Impact factor: 7.310

5.  Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia.

Authors:  Bianca Y Pingul; Hua Huang; Qingzhou Chen; Fatemeh Alikarami; Zhen Zhang; Jun Qi; Kathrin M Bernt; Shelley L Berger; Zhendong Cao; Junwei Shi
Journal:  iScience       Date:  2022-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.